Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00767494
Recruitment Status : Terminated (Project Cancelled)
First Posted : October 7, 2008
Last Update Posted : September 19, 2012
Information provided by (Responsible Party):
Alcon Research

Brief Summary:
The purpose of the study is to compare the IOP lowering efficacy of Travoprost/Brinzolamide dosed daily in the morning or evening, vs TRAVATAN dosed once daily in the evening, and vs. AZOPT dosed BID in patients with open-angle glaucoma or ocular hypertension.

Condition or disease Intervention/treatment Phase
Glaucoma Ocular Hypertension Drug: Travoprost/Brinzolamide fixed combination Drug: Azopt Drug: Travatan Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Study Start Date : October 2008
Actual Primary Completion Date : February 2009
Actual Study Completion Date : February 2009

Arm Intervention/treatment
Experimental: 1
Travoprost/Brinzolamide AM, Vehicle PM
Drug: Travoprost/Brinzolamide fixed combination
Eye Drops, suspension once daily
Experimental: 2
Travoprost/Brinzolamide PM, Vehicle AM
Drug: Travoprost/Brinzolamide fixed combination
Eye Drops, suspension once daily
Active Comparator: 3
Drug: Azopt
Eye Drop Suspension, 1 drop BID
Active Comparator: 4
Drug: Travatan
Eye Drop Solution, 1 drop BID

Primary Outcome Measures :
  1. Mean IOP [ Time Frame: 9, 11, and 16:00 time points at Week 12 ]

Secondary Outcome Measures :
  1. Mean diurnal IOP at Week 12 [ Time Frame: results pooled across 9,11, and 16:00 time points ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 YOA or older
  • Either gender or any race
  • OAG or OHT
  • Currently on stable (at least 4 weeks) IOP lowering medication
  • IOP at screening visit ≥ 18mmHg in at least one eye
  • Mean IOP in same eye (at both eligibility 1&2 visits
  • 24 and 36 mmHg at 9AM
  • 21 and 36 mmHg at 11AM and 4PM
  • Able to discontinue use of IOP lowering medication for a minimum wash out period of 5 to 28 days prior to eligibility visit 1

Exclusion Criteria:

Related to disease condition being investigated (OAG or OHT) in either eye

  • Severe central visual field loss
  • Angle shaffer grade < 2
  • C/D ratio >0.8(horizontal or vertical measurement)

Related to ocular patient history or current ocular condition in either eye

  • BSCVA worse than 55 ETDRS letters read (equivalent to approximately 20/80 Snellen or 0.25 decimal)
  • Ocular infection or inflammation or laser surgery within the last 3 months
  • Intraocular surgery or trauma with the last 6 months
  • Any abnormality preventing reliable applanation tonometry
  • History or chronic, recurrently or current severe inflammatory disease
  • History of or current clinically significant or progressive retinal disease
  • History of or current ocular pathology(including severe dry eye) that would affect the conduct of the study

Related to systemic or ocular medication in either eye

  • Allergy/hypersensitivity to study medications
  • Unable to discontinue glucocorticoid at least 4 weeks prior to the study or unable to remain off these medications during the study period
  • Use of oral CAIs during the study
  • Recent use (<4 weeks prior to the study) of Aspirin (>1 gram)
  • Less than 30 days stable dosing regimen of medications used on a chronic basis that may affect IOP
  • Therapy with another investigational agent within 30 days prior to the Screening Visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00767494

Brussels, Belgium
Sponsors and Collaborators
Alcon Research

Responsible Party: Alcon Research Identifier: NCT00767494     History of Changes
Other Study ID Numbers: C-07-63
First Posted: October 7, 2008    Key Record Dates
Last Update Posted: September 19, 2012
Last Verified: July 2009

Keywords provided by Alcon Research:
Open-angle glaucoma or ocular hypertension

Additional relevant MeSH terms:
Ocular Hypertension
Vascular Diseases
Cardiovascular Diseases
Eye Diseases
Antihypertensive Agents
Carbonic Anhydrase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action